Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease?

Table 1

Clinical and biochemical data of the studied groups

	Controls	AD	CJD	p Value
No of patients	47	38	14
Sex^1-150	29/18	15/23	7/7	NS
Age (y)^1-151	65 (10)	68 (10)	59 (4)	0.012
Disease duration (y)^1-151		3.6 (2.4)	0.4 (0.2)
Tau (pg/ml)^1-152	137 (110–220)	490 (366–796)	7942 (3787–14750)^1-153	<0.0001
Aβ42 (pg/ml)^1-152	734 (521–865)	375 (320–440)	312 (218–511)^1-154	<0.0001

↵1-150 Men/women, comparison with χ² test.
↵1-151 Mean (SD); age compared with one way ANOVA.
↵1-152 Median (quartiles), comparison with Kruskal-Wallis test.
↵1-153 Minimum=1240, maximum=26570.
↵1-154 n=12.

This Article

Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JNNP.
View free sample issue >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Highly increased CSF tau protein and decreased β-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer's disease?

This Article

Latest from Practical Neurology

BMJ Careers - Latest Neurology and Neurosurgery jobs